You just read:

BioMarin Submits Biologics License Application to U.S. Food and Drug Administration for Valoctocogene Roxaparvovec to Treat Hemophilia A

News provided by

BioMarin Pharmaceutical Inc.

Dec 23, 2019, 08:36 ET